問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Radiation Therapy

Division of General Internal Medicine

Division of General Surgery

Division of Urology

Digestive System Department

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-09-19

蘇柏榮Su, Po-Jung
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years 1 個月

  • pjsu@cgmh.org.tw

  • migelee@gmail.com

Recruiting Trial

108Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇柏榮

List

167Cases

2012-09-01 - 2017-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-02-01 - 2023-02-28

Phase III

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

  • Condition/Disease

    Renal Cell Carcinoma

  • Test Drug

    Atezolizumab

Participate Sites
6Sites

Terminated5Sites

莊正鏗
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-12-01 - 2022-12-31

Phase I/II

A phase Ib/II, multicenter open-label study of CS1001 in combination with regorafenib in patients with advanced or refractory solid tumors

  • Condition/Disease

    Advanced Refractory Solid Tumors

  • Test Drug

    CS1001 Regorafenib

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2011-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy

  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2021-03-02 - 2024-06-16

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-07-28 - 2020-11-01

Phase III

A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Avelumab (MSB0010718C)

Participate Sites
6Sites

Terminated6Sites

2016-07-05 - 2020-07-05

Phase II

ONO-4538 Phase II/III Study Multicenter, Open-Label, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Terminated10Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

2016-06-03 - 2021-02-01

Others

A Phase 1b/2 Open-label Study of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either 5-Fluorouracil or Capecitabine Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction

  • Condition/Disease

    Adenocarcinoma of the Stomach

  • Test Drug

    IMU-131

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 13 14 15 16 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB